Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T18:29:35.974Z Has data issue: false hasContentIssue false

INTRODUCTION

Published online by Cambridge University Press:  21 May 2002

David Barnett
Affiliation:
National Institute for Clinical Excellence (NICE), United Kingdom
Rod Taylor
Affiliation:
University of Birmingham, United Kingdom1

Extract

This special section is the written record of the second National Institute for Clinical Excellence (NICE) conference, which drew together experts in the fields of health technology assessment (HTA) from around the world. It includes a significant perspective from the pharmaceutical industry, whose partnership with the manufacturers of technologies (pharmaceuticals, devices, etc.) is of paramount importance to the successful future of the input of HTA into healthcare delivery. The importance of HTA as the basis of clinical decision making has never been more apparent. All clinicians are aware of the requirement that they provide the most up-to-date health care for their patients, who in turn appropriately consider this as a right. The need to ensure that this care is based on reliable evidence of clinical effectiveness is paramount. In addition, the need for all healthcare systems to consider costs as well as benefits has led to a further imposition on those who provide care to take into account value for money when considering the implementation of a new technology.

Type
Research Article
Copyright
© 2002 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)